Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway
Aging · 2024
DOI: 10.18632/aging.205972 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Yanbin Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Osteosarcoma, TOR Serine-Threonine Kinases, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Key Laboratory of Anesthesiology and Resuscitation, Huazhong University of Science and Technology, Ministry of Education, Wuhan 430022, China.
- Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430062, China.
Zitieren
APA
Zhang, Y., Zhang, T., Chen, L., Guo, Z., & Jiang, X. (2024). Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway. Aging. https://doi.org/10.18632/aging.205972
Vancouver
Zhang Y, Zhang T, Chen L, Guo Z, Jiang X. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway. Aging. 2024. doi:10.18632/aging.205972
BibTeX
@article{Zhang2024,
author = {Zhang, Yanbin and Zhang, Tao and Chen, Long and Guo, Zijun and Jiang, Xiaobing},
title = {Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205972}
}
EUVIMED